1. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
- Author
-
Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, and Cheng SH
- Subjects
- Administration, Oral, Animals, Carbamates pharmacology, Disease Models, Animal, Enzyme Inhibitors pharmacology, Gaucher Disease chemically induced, Gaucher Disease metabolism, Humans, Inositol analogs & derivatives, Liver metabolism, Lysosomes drug effects, Lysosomes enzymology, Mice, Quinuclidines pharmacology, Tissue Distribution, Treatment Outcome, Carbamates administration & dosage, Central Nervous System metabolism, Enzyme Inhibitors administration & dosage, Gaucher Disease drug therapy, Glucosyltransferases antagonists & inhibitors, Glycolipids metabolism, Quinuclidines administration & dosage
- Abstract
Gaucher disease (GD) is caused by a deficiency of glucocerebrosidase and the consequent lysosomal accumulation of unmetabolized glycolipid substrates. Enzyme-replacement therapy adequately manages the visceral manifestations of nonneuronopathic type-1 Gaucher patients, but not the brain disease in neuronopathic types 2 and 3 GD. Substrate reduction therapy through inhibition of glucosylceramide synthase (GCS) has also been shown to effectively treat the visceral disease. Here, we evaluated the efficacy of a novel small molecule inhibitor of GCS with central nervous system (CNS) access (Genz-682452) to treat the brain disease. Treatment of the conduritol β epoxide-induced mouse model of neuronopathic GD with Genz-682452 reduced the accumulation of liver and brain glycolipids (>70% and >20% respectively), extent of gliosis, and severity of ataxia. In the genetic 4L;C* mouse model, Genz-682452 reduced the levels of substrate in the brain by >40%, the extent of gliosis, and paresis. Importantly, Genz-682452-treated 4L;C* mice also exhibited an ~30% increase in lifespan. Together, these data indicate that an orally available antagonist of GCS that has CNS access is effective at attenuating several of the neuropathologic and behavioral manifestations associated with mouse models of neuronopathic GD. Therefore, Genz-682452 holds promise as a potential therapeutic approach for patients with type-3 GD.
- Published
- 2016
- Full Text
- View/download PDF